COVID-19 Vaccine Efficacy Study FAQ's - Kidney Wales
HomeNewsCOVID-19 Vaccine Efficacy Study FAQ’s

COVID-19 Vaccine Efficacy Study FAQ’s

 

Thank you for the fantastic response following our recent announcement of the decision to invest in two research very important studies aiming to discover how effective the Covid-19 vaccines are for dialysis and transplant patients.

 

Kidney Wales has back the ‘COVID-19 Immune Response and Vaccine Efficacy in Patients with Renal Disease and/or Transplantation’ study. A collaboration between the Welsh Kidney Research Unit, Cardiff University and active research clinicians working in the Cardiff Transplant Unit. The second part of this investment is teaming up with Kidney Research UK and the National Kidney Federation to co-fund the ‘Immunogenicity of COVID-19 Vaccination in Patients with Renal Disease’ study led by Imperial College London and the Francis Crick Institute

 

You have shown great interest and have lots of questions about these studies. So we have drafted our first frequently asked questions document to help answer some of them today.

 

FAQs – FAQs_Research into COVID vaccine efficacy_May 2021_PDF

 

As we stated previously, emerging evidence shows that having chronic kidney disease (CKD) at any stage significantly increases the risk of severe illness from Covid-19, with particular vulnerability for transplant and dialysis patients. Which is why investment in this research is so important.

If you would like to make a donation towards vital research into the effectiveness of the Covid-19 vaccines among people with kidney disease, Kidney Wales would welcome contributions through: